First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients
Rev. Soc. Bras. Med. Trop
; 51(2): 146-154, Mar.-Apr. 2018. tab, graf
Article
en En
| LILACS
| ID: biblio-897067
Biblioteca responsable:
BR1.1
ABSTRACT
Abstract INTRODUCTION:
Licensed for chronic hepatitis C treatment in 2011, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), which have high sustained viral responses (SVR), ushered a new era characterized by the development of direct-action drugs against the hepatitis C virus (HCV). The aim of this study was to analyze the effectiveness and safety of BOC and TVR administered with pegylated interferon and ribavirin and to share the experience of a Brazilian reference center.METHODS:
A retrospective descriptive study was conducted in patients with HCV genotype 1 infection who started treatment between July 2013 and December 2015. Data were collected using a computerized system.RESULTS:
A total of 115 subjects were included, of which 58 (50.4 %) had liver cirrhosis and 103 (89.6 %) used TVR. The overall SVR rate was 61.7 % (62.1 % for TVR and 58.3 % for BOC). The presence of cirrhosis was associated with a lower SVR rate, whereas patients who relapsed after prior therapy had a greater chance of showing SVR than did non-responders. The incidence of adverse drug reactions (ADRs) was high. Almost all patients (~100 %) presented with hematologic events. Furthermore, treatment had to be discontinued in 15 subjects (13 %) due to severe ADRs.CONCLUSIONS:
In conclusion, the SVR rates in our study were lower than those reported in pre-marketing studies but were comparable to real-life data. ADRs, particularly hematological ADRs, were more common compared to those in previous studies and resulted in a high rate of treatment discontinuity.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
LILACS
Asunto principal:
Antivirales
/
Inhibidores de Proteasas
/
Hepacivirus
/
Hepatitis C Crónica
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
País/Región como asunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Rev. Soc. Bras. Med. Trop
Asunto de la revista:
MEDICINA TROPICAL
Año:
2018
Tipo del documento:
Article
País de afiliación:
Brasil
Pais de publicación:
Brasil